罕见肿瘤靶点药物价值评估框架:国际进展与启示

The value assessment framework of target drugs for rare tumor:international progress and enlightenment

通过系统梳理欧盟、波兰、保加利亚在罕见病药物综合价值评估方面的做法,结合罕见肿瘤靶点突变疾病的特点,提出在中国开展罕见肿瘤靶点药物价值评估的建议,以期为临床和医保决策提供参考。

By systematically reviewing the practices of EU,Poland and Bulgaria in the comprehensive value assessment of drugs for rare diseases,and combining with the characteristics of rare tumor target mutation diseases,this paper puts forward suggestions on the value evaluation of rare tumor target drugs in China,in order to provide references for clinical and medical insurance decision-making.